Vepdegestrant Prolongs PFS in a Subgroup of Patients with ER-positive, HER2-negative Advanced Breast Cancer with ESR1 mutations By Ogkologos - June 30, 2025 778 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VERITAC-2 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Foodie Fridays: Apple Bok Choy Salad September 17, 2021 Seven Centres to form new Cancer Research UK network January 24, 2022 Study Explores Jaw Problem Linked to Zoledronic Acid, Finds Risk Factors January 28, 2021 EMA Recommends Extension of Therapeutic Indications for Selpercatinib August 25, 2022 Load more HOT NEWS Doctors Say Girl Has ‘Vanishing Bones’ That Are Slowly Disappearing From... Zolbetuximab plus CAPOX Prolongs Survival in CLDN18.2-positive, HER2-negative, Locally Advanced Unresectable... Taking Time for the Everyday Things in 2024 Neoadjuvant Histotype-Tailored Treatment with Trabectedin Not Inferior to Standard Chemotherapy with...
